Welcome to our dedicated page for Aurinia Pharmace SEC filings (Ticker: AUPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aurinia Pharmaceuticals Inc.'s SEC filings document the formal reporting record for a Canada-incorporated biopharmaceutical company commercializing LUPKYNIS and developing autoimmune-disease therapies. 8-K filings furnish operating and financial results, product revenue, license, collaboration and royalty revenue, research and development spending, guidance-related exhibits and other material-event disclosures.
The filings also cover proxy governance, executive appointments and compensatory arrangements, shareholder voting matters, capital-structure disclosures, share repurchase activity and material agreements. Recent transaction records include completed acquisition activity, tender-offer and merger mechanics, and contingent value right terms.
Robertson Stephen P. reported acquisition or exercise transactions in this Form 4 filing.
Aurinia Pharmaceuticals Inc. reported that its Chief Legal Officer, Stephen P. Robertson, received an equity compensation award in the form of 115,541 performance stock units. These units were granted at no cash cost per unit and increase his direct holdings to 621,402 common shares or share-based units reported in this filing.
The footnote explains that each performance stock unit represents a contingent right to receive one common share of Aurinia. The 115,541 units vest in two tranches on the third and fifth anniversaries of the grant date, only if Aurinia’s common shares reach target prices that represent significant increases from the grant-date share price before each vesting date.
Hearne Michael S reported acquisition or exercise transactions in this Form 4 filing.
Aurinia Pharmaceuticals Inc. reported that Chief Financial Officer Michael S. Hearne received new equity compensation awards. He was granted 116,144 performance stock units, each representing a contingent right to receive one common share, and 70,230 employee stock options.
The PSUs vest in multiple tranches based on Aurinia’s share price performance and time-based conditions, while the options have a strike price of $15.28 per share and expire on May 18, 2036. These are compensation-related grants rather than open-market share purchases or sales.
Aurinia Pharmaceuticals Inc. reported that Chief Operating Officer Ryan Cole received new equity awards. He was granted 116,144 performance stock units, each representing a contingent right to receive one common share, with vesting tied to share-price targets and time-based conditions. He also received an option grant for 70,230 shares of common stock at an exercise price of $15.28 per share, expiring in 2036. These awards are compensation-related grants, and no open-market share purchases or sales were reported in this filing.
Morgan Stanley Smith Barney LLC intends to sell 3,136,201 shares of Common Stock on 05/11/2026 via the exercise of options under a registered plan.
The filing shows an aggregate value of $49,677,423.84 and reports 128,601,671 shares outstanding as of 05/11/2026; the method of sale is listed as cash.
Proposed sale of common stock by a holder via Form 144. The filing lists 717,688 common shares associated with an exercise of options under a registered plan with an indicated trade date of 05/11/2026. The sales method is listed as cash.
Morgan Stanley Smith Barney LLC Executive Financial Services filed a notice to sell 500,503 shares of Common Stock on 05/11/2026 related to an exercise of options under a registered plan. The filing lists an aggregate value of $7,927,967.52 and identifies the exchange as NASDAQ.
Aurinia Pharmaceuticals Inc. completed its acquisition of Kezar Life Sciences through a tender offer and follow-on merger. Kezar stockholders received $6.955 in cash per share plus one contingent value right, with 5,927,580 shares tendered, representing about 80.24% of outstanding shares at expiration.
After the tender offer closed, Aurinia merged its subsidiary into Kezar under Delaware law, making Kezar a wholly owned subsidiary. In-the-money Kezar stock options became fully vested and were cashed out for the cash portion of the offer plus CVRs, while out-of-the-money options were cancelled with no payment. Kezar’s employee stock purchase plan was terminated immediately before the merger became effective.
Aurinia Pharma completed its tender offer and merger for Kezar Life Sciences. The Offer provided $6.955 per share in cash plus one nontransferable contingent value right (CVR) per share. A total of 5,927,580 shares were validly tendered, representing approximately 80.24% of outstanding shares.
All conditions were satisfied or waived, Purchaser accepted for payment the tendered shares, and on May 11, 2026 Merger Sub merged into Kezar under Section 251(h) of the DGCL, making Kezar a wholly owned subsidiary of Parent. Kezar shares ceased trading on Nasdaq and steps were taken to delist and suspend reporting obligations.
Aurinia Pharma completed its tender offer and merger for Kezar Life Sciences. The Offer provided $6.955 per share in cash plus one nontransferable contingent value right (CVR) per share. A total of 5,927,580 shares were validly tendered, representing approximately 80.24% of outstanding shares.
All conditions were satisfied or waived, Purchaser accepted for payment the tendered shares, and on May 11, 2026 Merger Sub merged into Kezar under Section 251(h) of the DGCL, making Kezar a wholly owned subsidiary of Parent. Kezar shares ceased trading on Nasdaq and steps were taken to delist and suspend reporting obligations.
Aurinia Pharmaceuticals delivered a stronger Q1 2026, driven by growth in its lupus nephritis drug LUPKYNIS. Total revenue rose to $77.7 million from $62.5 million, as net product sales increased 23% to $73.6 million and collaboration revenue with Otsuka also expanded.
Net income improved to $34.4 million from $23.3 million, with gross margin rising to 92% from 86% as lower low-margin sales to Otsuka reduced cost of revenue. Operating cash flow surged to $32.6 million, up from $1.3 million, reflecting higher profitability and working-capital shifts.
Aurinia ended the quarter with $378.8 million in cash, equivalents, restricted cash and investments, even after repurchasing 2.5 million shares for $36.8 million; cumulative buybacks since February 2024 total 23.1 million shares for $211.0 million. The company signed a definitive agreement to acquire Kezar Life Sciences for $6.955 per share in cash plus a contingent value right, targeting additional autoimmune and oncology assets. Leadership also changed, with Kevin Tang appointed CEO, Ryan Cole COO and Michael Hearne CFO, replacing the prior executive team, which remains as consultants during a transition period.
Aurinia Pharmaceuticals reported strong results for the three months ended March 31, 2026. Total revenue reached $77.7 million, up 24% from $62.5 million a year earlier, driven mainly by LUPKYNIS net product sales of $73.6 million, up 23%.
Net income was $34.4 million, a 48% increase from $23.3 million, with diluted earnings per share rising to $0.25 from $0.16. Operating cash flow improved sharply to $32.6 million from $1.3 million, while cash, cash equivalents, restricted cash and investments totaled $378.8 million as of March 31, 2026.
The company repurchased 2.5 million common shares for $36.2 million during the quarter and reaffirmed 2026 guidance, targeting total revenue of $315–$325 million and LUPKYNIS net product sales of $305–$315 million.